文献速递消化与肝胆胰病理细胞病理与分子病理

食管原发性恶性黑色素瘤的临床病理与分子特征综合分析

Comprehensive clinicopathological and molecular analysis of primary malignant melanoma of the oesophagus.
PubMed 文献 · Histopathology · 2020-09-20

本研究通过下一代测序和免疫组化分析13例食管原发性恶性黑色素瘤(PMME)和10例皮肤恶性黑色素瘤(SKMM),揭示PMME的3年总生存率为23.1%、中位生存期11.9个月。PMME中NF1突变最常见(30%),未检测到BRAF突变,肿瘤突变负荷显著低于SKMM(P=0.030)。RAS-MAPK通路是PMME主要涉及通路,其遗传特征类似黏膜/肢端黑色素瘤而非SKMM。

要点

  • PMME预后差,3年总生存率23.1%,中位生存期11.9个月。
  • PMME中NF1突变最常见(30%),未检出BRAF突变。
  • PMME肿瘤突变负荷显著低于SKMM(P=0.030),免疫治疗可能效果有限。

核心结论

  • RAS-MAPK通路是PMME主要涉及通路之一。
  • PMME遗传特征类似黏膜/肢端黑色素瘤,不同于SKMM。
  • 部分PMME可能存在可靶向的突变。
  • 免疫治疗对多数PMME似乎效果较差。

研究设计与样本

  • 回顾性分析13例PMME和10例SKMM病例。
  • 采用下一代测序(NGS)和免疫组化分析临床病理与分子病理。

主要发现

  • PMME患者3年总生存率为23.1%,中位生存时间为11.9个月。
  • 3例(23.1%)PMME呈乳头状结构,8例(61.5%)有淋巴结转移。
  • NF1突变最常见(30%,10例PMME中),其他突变包括SF3B1(20%)、KRAS(10%)、BRCA2(10%)、KIT(10%)和TP53(10%)。
  • PMME中未检测到SKMM常见的BRAF突变。
  • PMME肿瘤突变负荷显著低于SKMM(P=0.030),无病例显示高度微卫星不稳定。

临床怎么用

  • PMME应进行分子检测以识别可靶向突变(如NF1、SF3B1、KRAS、BRCA2、KIT、TP53)。
  • PMME免疫治疗疗效可能有限,需谨慎评估。
  • PMME与SKMM分子特征不同,治疗策略应区别对待。

局限性

  • 样本量较小(13例PMME和10例SKMM)。
  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This study was performed to elucidate the clinicopathological characteristics, genetic alterations and therapeutic targets of primary malignant melanoma of the oesophagus (PMME). METHODS AND RESULTS: The clinicopathology and molecular pathology of 13 PMME cases and 10 skin malignant melanoma (SKMM) cases were analysed with next-generation sequencing (NGS) and immunohistochemistry. The 3-year overall survival rate and the median survival time for PMME patients were 23.1% and 11.9 months, respectively. Three (23.1%) and eight (61.5%) PMME cases showed a papillary structure and lymph node metastasis, respectively. DNA and RNA hybridization capture-based NGS analysis revealed that NF1 was the most frequently mutated gene (30%) in 10 of the PMME cases. Other mutations detected in PMME included SF3B1 (20%), KRAS (10%), BRCA2 (10%), KIT (10%) and TP53 (10%) mutations. Commonly detected BRAF mutations in SKMM were not detected in PMME. Immunohistochemistry and mutation status were concordant between p53/c-Kit and TP53/KIT, respectively. Focal expression of programmed death-ligand 1 was observed in one PMME sample. The tumour mutation burden in PMME was significantly lower than that in SKMM (P = 0.030). No PMME case showed high microsatellite instability. RNA sequencing revealed a distinctive pattern with respect to RNA expression. T-cell co-stimulation differed between PMME and SKMM. CONCLUSIONS: The RAS-mitogen-activated protein kinase pathway is one of the main pathways involved in PMME. The genetic profile of PMME was similar to that of mucosal/acral melanoma, but differed from the SKMM profile. A subset of PMMEs may contain actionable mutations. Immunotherapy seemed to be less effective for most PMMEs in this series.

来源:Histopathology,查看原文。版权归原作者所有。

引用

  1. Tsuyama S, Kohsaka S, Hayashi T, et al. Comprehensive clinicopathological and molecular analysis of primary malignant melanoma of the oesophagus. Histopathology. 2020. PMID: 32654197. doi:10.1111/his.14210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。